騰訊(00700.HK)優圖新天體搜索方案已找到22個脈衝星候選體
《新浪科技》報道,騰訊(00700.HK)於2022世界人工智能大會期間披露「探星計劃」最新成果,截至昨日(1日),優圖新天體搜索方案已從巡天觀測數據中找到22個脈衝星候選體。
騰訊和國家天文台在去年的世界人工智能大會上共同啟動「探星計劃」,雙方基於騰訊優圖實驗室的計算機視覺技術和騰訊雲的計算能力,提出用AI幫助「中國天眼」FAST處理每天接收到的龐大數據,並通過視覺AI分析找到脈衝星線索。
騰訊優圖實驗室研究總監汪鋮傑表示,FAST在一周內產生的數據大約相當於3,000萬張信號圖,如以人工肉眼處理,按照每秒1張的速度,即使每天工作24小時,也需時約一年才能完成;而通過AI預篩選,3天就可以完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.